Dr. Reddy's Laboratories Says US FDA Approves Rituximab Biosimilar for US Market

MT Newswires Live08-03

Dr. Reddy's Laboratories (RDY) said in a regulatory filing that the US Food and Drug Administration has approved its rituximab biosimilar for the US market.

The approval follows a recent Pre-License Inspection done by the US FDA at the biologics manufacturing plant in Hyderabad, India, the company said in a statement filed Monday.

Dr. Reddy's said that under a commercialization deal, Fresenius Kabi has the exclusive rights to commercialize the product in the US.

Rituximab is approved in the US to treat adults with blood cancers and autoimmune diseases including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis, the company said.

Price: 12.10, Change: +0.25, Percent Change: +2.11

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2656737738?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 22:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656737738","market":"us","top_or_hot":-1,"title":"Dr. Reddy's Laboratories Says US FDA Approves Rituximab Biosimilar for US Market","media":"MT Newswires Live","content":"<html><body><p> Dr. Reddy's Laboratories (RDY) said in a regulatory filing that the US Food and Drug Administration has approved its rituximab biosimilar for the US market.</p><p>The approval follows a recent Pre-License Inspection done by the US FDA at the biologics manufacturing plant in Hyderabad, India, the company said in a statement filed Monday.</p><p>Dr. Reddy's said that under a commercialization deal, Fresenius Kabi has the exclusive rights to commercialize the product in the US.</p><p>Rituximab is approved in the US to treat adults with blood cancers and autoimmune diseases including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis, the company said.</p><p>Price: 12.10, Change: +0.25, Percent Change: +2.11</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dr. Reddy's Laboratories Says US FDA Approves Rituximab Biosimilar for US Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDr. Reddy's Laboratories Says US FDA Approves Rituximab Biosimilar for US Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-03 22:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Dr. Reddy's Laboratories (RDY) said in a regulatory filing that the US Food and Drug Administration has approved its rituximab biosimilar for the US market.</p><p>The approval follows a recent Pre-License Inspection done by the US FDA at the biologics manufacturing plant in Hyderabad, India, the company said in a statement filed Monday.</p><p>Dr. Reddy's said that under a commercialization deal, Fresenius Kabi has the exclusive rights to commercialize the product in the US.</p><p>Rituximab is approved in the US to treat adults with blood cancers and autoimmune diseases including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis, the company said.</p><p>Price: 12.10, Change: +0.25, Percent Change: +2.11</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2656737738","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2656737738","pubTimestamp":1785766579,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Dr. Reddy's Laboratories  said in a regulatory filing that the US Food and Drug Administration has approved its rituximab biosimilar for the US market.The approval follows a recent Pre-License Inspection done by the US FDA at the biologics manufacturing plant in Hyderabad, India, the company said in a statement filed Monday.Dr. Reddy's said that under a commercialization deal, Fresenius Kabi has the exclusive rights to commercialize the product in the US.Rituximab is approved in the US to treat adults with blood cancers and autoimmune diseases including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis, the company said.Price: 12.10, Change: +0.25, Percent Change: +2.11","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","LU0348744763.USD":"ALLIANZ ASIA PACIFIC INCOME \"A\" (USD) INC","BK4585":"ETF&股票定投概念","RDY":"如瑞迪博士","BK4596":"哈里斯概念","BK4007":"制药","LABU":"三倍做多标普生物-Direxion","BK7016":"应用软件","BK4523":"印度概念","BK4588":"碎股","RDY.AU":"READYTECH HOLDINGS LTD","BK4557":"大麻股"},"translate_title":"Reddy's Laboratories 表示美国 FDA 批准利妥昔单抗生物仿制药进入美国市场","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RDY":1,"RDY.AU":1,"LABU":1.5},"content_text":"Dr. Reddy's Laboratories (RDY) said in a regulatory filing that the US Food and Drug Administration has approved its rituximab biosimilar for the US market.The approval follows a recent Pre-License Inspection done by the US FDA at the biologics manufacturing plant in Hyderabad, India, the company said in a statement filed Monday.Dr. Reddy's said that under a commercialization deal, Fresenius Kabi has the exclusive rights to commercialize the product in the US.Rituximab is approved in the US to treat adults with blood cancers and autoimmune diseases including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis, the company said.Price: 12.10, Change: +0.25, Percent Change: +2.11","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656737738","isCrawlerRequest":true}